An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).
Carol A Langford, Paul A Monach, Ulrich Specks...
https://pubmed.ncbi.nlm.nih.gov/24323392/Actively Recruiting
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-04-03
42
Participants Needed
1
Research Sites
21 weeks
Total Duration
Researchers are investigating the best treatment options for patients with granulomatosis with polyangiitis GPA who do not respond well to standard therapies. This study aims to compare three salvage treatments to induce remission in these patients a combination of rituximab with a conventional disease-modifying antirheumatic drug cDMARD, tocilizumab, and tofacitinib. GPA is a type of inflammation affecting blood vessels, and managing patients with ongoing disease activity despite standard care remains challenging. The study involves three treatment groups. One group receives rituximab weekly for four weeks followed by maintenance doses at weeks 24 and 52, combined with a cDMARD chosen by the doctor preferably methotrexate, but azathioprine or mycophenolate mofetil may be used. Another group receives weekly subcutaneous injections of tocilizumab, and the third group takes oral tofacitinib twice daily starting at week 0 through week 52. Each treatment is studied to understand its ability to help patients achieve remission. Participants will be monitored regularly throughout the study, with key assessments at weeks 12, 24, 26, and 52. Researchers will evaluate responses including remission rates, disease activity as assessed by doctors and patients, patient-reported outcomes, and use of corticosteroids. Safety will be monitored by tracking adverse events and laboratory tests. The study is designed to last at least 52 weeks of treatment with detailed follow-up to better understand the effects of these therapies on GPA management.
CONDITIONS
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
J
Jonathan London, MD
A
Alice CAMARA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Assistance Publique - Hôpitaux de Paris
Lead Sponsor
URC-CIC Paris Descartes Necker Cochin
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 52 weeks
Participants receive one of the study drugs: Rituximab plus a conventional DMARD, Tocilizumab, or Tofacitinib to manage granulomatosis with polyangiitis that has not responded adequately to previous standard therapies.
Weekly visits for the first 4 weeks, then visits at week 24 and week 52
Duration - Up to 52 weeks
Participants are monitored for treatment response, safety, and disease activity after completing the treatment phase.
Visits at week 12, 24, 26, and 52 for assessments
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Carol A Langford, Paul A Monach, Ulrich Specks...
https://pubmed.ncbi.nlm.nih.gov/24323392/Alvise Berti, Roscoe Warner, Kent Johnson...
https://pubmed.ncbi.nlm.nih.gov/31320177/M Yates, R A Watts, I M Bajema...
https://pubmed.ncbi.nlm.nih.gov/27338776/Ryota Sakai, Tsuneo Kondo, Takahiko Kurasawa...
https://pubmed.ncbi.nlm.nih.gov/28733791/Julia U Holle, Christin Dubrau, Karen Herlyn...
https://pubmed.ncbi.nlm.nih.gov/22021864/Bernhard Hellmich, Oliver Flossmann, Wolfgang L Gross...
https://pubmed.ncbi.nlm.nih.gov/17170053/John H Stone, Peter A Merkel, Robert Spiera...
https://pubmed.ncbi.nlm.nih.gov/20647199/Alvise Berti, Giulio Cavalli, Corrado Campochiaro...
https://pubmed.ncbi.nlm.nih.gov/25841802/Assistance Publique - Hôpitaux de Paris
Lead Sponsor
URC-CIC Paris Descartes Necker Cochin
Collaborating Sponsor